ClinicalTrials.gg
TerminatedNCT04190082Updated Feb 15, 2023

The Effect of Bispectral Index Monitoring on Recovery From Deep Sedation

An observational study in Cerebral Palsy, sponsored by Yeungnam University College of Medicine. Terminated at 1 site in Korea, Republic of. Open to participants aged 3 Years to 12 Years. Per ClinicalTrials.gov, last updated 2023-02-15.

Sponsored by Yeungnam University College of Medicine · Observational

Why this study was terminated
No more participants enrolled.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
12
Ages
3 Years to 12 Years
Sex
All
01

Study summary

The purpose of this study was to compare BIS (bispectral index) monitoring and clinical sedation scale assessment on the recovery time and propofol usage from deep propofol sedation in children with cerebral palsy who received botulinum toxin injection.

Read the detailed description

After arrival in the preoperative holding area, children were randomly allocated into two groups using a computer-generated random assignment scheme. Five minutes before propofol sedation, remifentanil is administered intravenously at 0.025 μg / kg / min for analgesic effect and continued throughout the sedation process until just before the end of the procedure. Five minutes after remifentanil administration, 2 mg / kg of propofol mixed with 1 mg / kg of lidocaine was administered over 30 seconds, followed by continuous infusion at 100 μg / kg / min. Group C is monitored using UMSS(University of Michigan Sedation Scale) scores every three minutes, and group B is monitored using BIS score until deep sedation. Deep sedation is defined based on UMSS score of 3-4 and BIS score of 65 ± 5. If the sedation score is determined to have reached a deep sedation, a botulinum toxin injection is given by a practitioner blind to how to assess the depth of sedation. Independent investigator who is blind to group assignement assesses the oxygen saturation, respiration, and blood pressure, recovery time from sedation, and adverse events during and after sedation.

02

Conditions studied

  • Cerebral Palsy

Browse trials for

Keywords

  • Cerebral palsy
  • Botulinum toxin
  • Bispectral index monitor
  • Deep sedation
  • Recovery
03

In context

Cerebral Palsy

1,936 studies on the registry are indexed under Cerebral Palsy; 458 are open to participants now.

This study's enrollment of 12 is below the median of 63 across 472 observational studies indexed under Cerebral Palsy.

Browse Cerebral Palsy studies →

Lead sponsor

Yeungnam University College of Medicine is the lead sponsor of 32 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
3 Years to 12 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

children with spastic cerebral palsy primary care clinic (rehabilitation)

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 3-12 years old children with spastic cerebral palsy receiving botulinum toxin injection with deep sedation
  • Physical Status 1-2

Exclusion criteria

Exclusion Criteria:

  • > 30 kg/m2
  • unstable heart disease
  • Anticipated difficult airway including congenital facial or airway anomaly
  • Recent upper respiratory tract infection ( \< 2 weeks)
  • Gastroesophageal reflux
  • Allergy history to propofol, remifentanil or any drug used during procedure
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
12 participants (actual)
Patient registry
No

Groups and cohorts

  • Group Control

    Group who maintains deep sedation using the University of Michigan sedation scale (UMSS) score.

  • Group BIS

    Group who maintain deep sedation using Bispectral Index (BIS) score.

06

What researchers measure

Primary outcomes

  1. recovery

    Time taken to recover based on the Physiological CBD score (\>12) from deep sedation

    Time frame: Immediately after discontinuation of propofol infusion used for botulinum toxin injection

Secondary outcomes

  1. Propofol dose

    Amount of propofol to maintain deep sedation for botulinum toxin injection

    Time frame: Immediately after discontinuation of propofol infusion used for botulinum toxin injection

07

Study locations

1 site
  • Location Yeungnam University Hospita
    Daegu, 42415, Korea, Republic of
08

References and documents

Publications

  • Choudhry DK, Brenn BR. Bispectral index monitoring: a comparison between normal children and children with quadriplegic cerebral palsy. Anesth Analg. 2002 Dec;95(6):1582-5, table of contents. doi: 10.1097/00000539-200212000-00020. PubMed 12456420 ↗
  • Malviya S, Voepel-Lewis T, Tait AR. A comparison of observational and objective measures to differentiate depth of sedation in children from birth to 18 years of age. Anesth Analg. 2006 Feb;102(2):389-94. doi: 10.1213/01.ANE.0000184045.01780.73. PubMed 16428530 ↗
  • Saricaoglu F, Celebi N, Celik M, Aypar U. The evaluation of propofol dosage for anesthesia induction in children with cerebral palsy with bispectral index (BIS) monitoring. Paediatr Anaesth. 2005 Dec;15(12):1048-52. doi: 10.1111/j.1460-9592.2005.01658.x. PubMed 16324022 ↗

Individual participant data

Plan to share: No — no plan to share our data

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2021 to primary completion in Dec 2022, 19 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 4, 2019
First posted
Dec 9, 2019
StartActual
May 1, 2021
Primary completionActual
Dec 9, 2022
CompletionActual
Dec 9, 2022
Last update
Feb 15, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 15, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04190082
Lead sponsor
Yeungnam University College of Medicine
Responsible party
Sung Mee Jung (Professor, Yeungnam University College of Medicine) — Principal investigator
First posted
Dec 9, 2019
Start date
May 1, 2021
Primary completion
Dec 9, 2022
Completion
Dec 9, 2022
Last update
Feb 15, 2023

Study contacts

Sung Mee Jung, MD,PhD
principal investigator · Yeungnam University Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion